Pipeline Review on Liver Transplant Rejection – H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Liver Transplant Rejection – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.

Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Liver Transplant Rejection – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 2, 1, 1, 3 and 1 respectively. (Read more…) Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 2, 1 and 1 molecules, respectively.

Liver Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned

• Alexion Pharmaceuticals Inc
• Dompe Farmaceutici SpA
• F4 Pharma GmbH
• Helocyte Biosciences Inc
• Novartis AG
• Pharmapraxis
• Quell Therapeutics Ltd
• TRACT Therapeutics Inc
• Veloxis Pharmaceuticals AS

Reasons to Buy

1. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
2. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
3. Find and recognize significant and varied types of therapeutics under development for Liver Transplant Rejection (Immunology).
4. Classify potential new clients or partners in the target demographic.
5. Develop tactical initiatives by understanding the focus areas of leading companies.
6. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
7. Formulate corrective measures for pipeline projects by understanding Liver Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
8. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
9. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Liver Transplant Rejection – Overview
• Liver Transplant Rejection – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Liver Transplant Rejection – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Liver Transplant Rejection – Companies Involved in Therapeutics Development
• Liver Transplant Rejection – Drug Profiles
• Cellular Immunotherapy for Liver Transplant Rejection – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Cellular Immunotherapy for Liver Transplantation – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Cellular Immunotherapy for Liver Transplantation – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• eculizumab – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• FX-06 – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Gene Therapy for High-Grade Glioma and Liver Transplantation – Drug Profile
• Liver Transplant Rejection – Dormant Projects
• Liver Transplant Rejection – Discontinued Products
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ma1yi8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900